AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic stroke
In Vivo
AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest . AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mice (C57BL/6J, 8-12 week-old, 25-30 g)Dosage: 5 mg/kg Administration: Treated by i.p. injection Result: Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62.
IC50& Target:Aquaporin-4 (AQP4)
사양
사양 및 순도
10mM in DMSO
생화학 및 생리적 메커니즘
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic stroke.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.